Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

Hims & Hers Health, Inc. ($HIMS) stands at an inflection point as it prepares to report first-quarter 2026 earnings on May 11, with Wall Street closely monitoring how the company's strategic pivot away from compounded GLP-1 products will impact its core growth narrative. Following a landmark patent settlement with Novo Nordisk in March, the telehealth provider secured exclusive rights to distribute brand-name Wegovy and Ozempic through its platform—a monumental shift that fundamentally reorients its obesity and diabetes treatment offerings. However, the timing of this agreement, which came late in the quarter, means the full financial impact remains largely unforeseen, making this earnings report a critical barometer for investor confidence in management's ability to execute this new strategic direction.

The Novo Nordisk Deal: A Watershed Moment

The settlement agreement with Novo Nordisk represents perhaps the most significant strategic development in Hims & Hers' recent history. Under the terms of the deal, the company gained the right to sell the pharmaceutical giant's flagship GLP-1 products—Wegovy for weight management and Ozempic for diabetes—directly through its digital platform. In exchange, Hims & Hers committed to cease all advertising and marketing of compounded GLP-1 medications, effectively dismantling a business line that had become a critical growth engine during the obesity drug boom.

This agreement carries profound implications:

• Transition from compounded to branded products eliminates a significant margin advantage previously enjoyed by the company
• Novo Nordisk's supply chain and regulatory backing provides legitimacy and reduced liability exposure
• Elimination of compounded GLP-1 marketing removes a contentious regulatory and reputational vulnerability
• Access to premium-priced branded alternatives opens new revenue streams despite lower margins

The timing of the deal's availability—becoming operational only in late Q1—means analysts and investors will be watching closely for any early indicators of adoption rates, pricing, and customer transition from compounded to branded offerings. This lag effect suggests that Q1 results may not fully capture the magnitude of the strategic shift, keeping the market in a state of heightened anticipation.

Wall Street's Earnings Expectations

Analysts tracking $HIMS have set relatively modest expectations for the quarter, reflecting uncertainty around the transition period and the limited implementation window:

• Earnings Per Share (EPS): 3-4 cents, representing steady profitability
• Total Revenue: $616-619 million, indicating continued double-digit growth trajectory
• Subscriber Growth Target: Above 2.5 million total subscribers, a critical metric for assessing platform expansion
• Analyst Rating: Consensus remains a Hold despite 24% upside potential to consensus price targets

The modest EPS guidance reflects the earnings accretion challenges posed by the compounded-to-branded transition. While branded medications carry superior regulatory standing and clinical legitimacy, they also come with substantially lower gross margins compared to the high-margin compounded formulations that previously drove profitability. This trade-off—accepting near-term margin compression for long-term strategic positioning—will be a key talking point for management during earnings calls.

Subscriber growth remains the critical barometer. Hitting the above-2.5 million target would demonstrate the platform's continued ability to attract and retain users across its expanding portfolio of health services. Given the company's historical momentum in this metric, the bar appears achievable, though any moderation in subscriber acquisition would raise questions about market saturation or competitive pressures from rivals like Ro Holdings and traditional pharmacy chains entering the telehealth space.

Market Context: The GLP-1 Battleground Intensifies

The Hims & Hers earnings preview arrives at a pivotal moment in the broader GLP-1 market dynamics. The obesity and diabetes pharmaceutical sector has become increasingly crowded and contentious, with multiple players competing for market share:

The Compounded Alternative Era: For much of 2024-2025, companies like Hims & Hers leveraged compounded GLP-1 products as a lower-cost, faster-to-market alternative to branded medications. These formulations, while chemically similar to brand-name products, offered significant cost advantages and faster delivery timelines. However, they also attracted regulatory scrutiny from the FDA and faced reputational concerns around quality control and consistency.

Branded Products and Novo Nordisk's Market Power: Novo Nordisk's dominance in the GLP-1 category—with Wegovy and Ozempic commanding substantial market share—has created an asymmetric competitive landscape. The pharmaceutical giant's clinical evidence, manufacturing standards, and regulatory approval provide decisive advantages that compounded alternatives struggle to match. By securing distribution rights through Hims & Hers, Novo Nordisk essentially neutralized a significant distribution threat while maintaining pricing power.

Competitive Implications: Traditional pharmaceutical distribution channels, major pharmacy chains like CVS and Walgreens, and direct-to-consumer telehealth platforms are all competing fiercely for GLP-1 patients. Hims & Hers' access to branded products positions it differently than competitors relying solely on compounded alternatives or traditional pharmacy networks, but it also means accepting lower margins in exchange for premium clinical credibility.

Investor Implications: Why This Earnings Report Matters

For equity investors in $HIMS, this earnings report serves as a critical inflection point for several reasons:

Profitability Sustainability: The transition from high-margin compounded products to lower-margin branded offerings creates near-term EPS headwinds. Investors will scrutinize whether management's guidance accounts for this reality and whether other revenue streams can offset the margin compression.

Growth Rate Trajectory: Subscriber growth will take center stage as evidence that the platform can expand beyond its reliance on GLP-1 products alone. Achieving above-2.5 million subscribers would suggest the company's broader telehealth services (mental health, primary care, etc.) are providing diversification.

Competitive Moat: The exclusive distribution rights to Wegovy and Ozempic represent a significant competitive advantage. However, investors must assess whether this moat is durable or whether Novo Nordisk might expand distribution to competing platforms over time.

Regulatory Risk Mitigation: The settlement with Novo Nordisk eliminates potential regulatory actions against compounded GLP-1 marketing and distribution. This reduces tail risk and provides strategic clarity, which could support a valuation re-rating if properly communicated to market participants.

The 24% upside potential embedded in the consensus price target suggests that the market is pricing in conservative near-term execution, with significant opportunity for positive surprise if management demonstrates strong early adoption of branded products and maintains subscriber momentum.

Looking Ahead: The Path Forward

As Hims & Hers enters its earnings season, the company faces a delicate balancing act: maintaining investor confidence during a strategic transition while laying the groundwork for accelerated growth in subsequent quarters when branded GLP-1 products are in full operational implementation. Management's commentary on customer reception to branded products, pricing strategy, margin outlook, and competitive positioning will be scrutinized as closely as the reported numbers themselves.

The broader context—a transforming digital health landscape increasingly dominated by pharmaceutical incumbents—suggests that pure-play telehealth platforms must develop differentiated distribution capabilities and clinical partnerships to survive. Hims & Hers' agreement with Novo Nordisk represents exactly such an adaptation, trading margin for market access and regulatory legitimacy. Whether this strategy ultimately proves accretive to shareholder value will become clearer in the quarters following May 11's earnings announcement.